The impact on the pharma industry revenues will be limited for around 12-18 months, post which the product portfolio will evolve to overcome the dip in the revenue. For consumers this pricing policy would help to some extent with the issue of affordability. Overall this is a solution which the industry and Government can live with as opposed to the alternative price control formulas based on cost of production etc.
– Sujay Shetty, Leader Pharma Life Sciences, PwC India